Lamivudine Viatris (Lamivudine)

Lamivudine is a nucleoside analogue that is converted inside cells to its active triphosphate form. This active metabolite competes with natural nucleotides for incorporation into viral DNA by reverse transcriptase, causing premature chain termination and preventing the virus from replicating its genetic material.

The dosage of lamivudine is individualized by the prescribing healthcare professional based on the patient’s condition, weight, renal function and other clinical factors. Patients should follow the dose and schedule provided by their prescriber and not adjust the amount without medical advice.

Lamivudine may be used during pregnancy when the potential benefits outweigh any possible risks to the fetus, as determined by a qualified clinician. Limited data are available for breastfeeding, and a healthcare provider should assess the risk‑benefit profile before continuing therapy while nursing.

To order Lamivudine Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class and is often combined with other antiretrovirals for synergistic effect. Compared with older NRTIs such as zidovudine, lamivudine generally has a more favorable tolerability profile and a lower incidence of mitochondrial toxicity, though drug‑specific interactions must still be considered.

Lamivudine Viatris should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Lamivudine Viatris is taken orally, usually as a tablet, with or without food as directed by a healthcare professional. The exact administration schedule, including timing and whether it is taken once or twice daily, is determined by the prescriber based on the individual treatment plan.

Serious risks include lactic acidosis, severe hepatotoxicity, and hypersensitivity reactions such as rash or Stevens‑Johnson syndrome. Patients should be educated to seek immediate medical attention if they experience unexplained fatigue, abdominal pain, rapid breathing, jaundice, or severe skin reactions.

Lamivudine is contraindicated in patients with known hypersensitivity to the drug or any of its components. Caution is also advised for individuals with pre‑existing severe liver disease, mitochondrial disorders, or those receiving contraindicated medications such as didanosine or stavudine.